Pharmaceuticals APAC News & Press Release Distribution

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...

2024-06-02 08:00 5885

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-06-02 08:00 5432

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-06-02 08:00 7109

SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis

ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of AKANTIOR® (polihexanide under the international non-proprietary name),...

2024-05-31 15:00 2942

Record numbers expected at CPHI & PMEC China 2024 as Asian markets boom

Domestic and international markets in Asia surging as CPHI & PMEC China welcomes 60,000 attendees and 3500 exhibitors SHANGHAI and AMSTERDAM, May 31, 2024 /PRNewswire/ -- CPHI & PMEC China (June 19-21st) returns to the Shanghai New International Expo Center amid s...

2024-05-31 11:18 4126

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

* TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. * Reported median radiographic progression-free survival (rPFS) is 8.8 months. * Builds on prior data from th...

2024-05-31 07:19 3314

LumaCina announces availability of Oral Morphine pain medication for New Zealanders

PERTH, Australia and MIAMI, May 31, 2024 /PRNewswire/ -- LumaCina, the pharmaceutical supplier and marketing division ofBridgewest Perth Pharma announce new production of Oral Morphine to meet critical drug shortage inNew Zealand. The shortfall of Oral Morphine has become increasingly concerning...

2024-05-31 05:17 2879

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024

SAN JOSE, Calif., May 30, 2024 /PRNewswire/ -- Teikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm® ("lidocaine 5% patch as lidocaine cataplasms") for the treatment of Post Herpetic Neuralgia (PHN) inChina. TPU entered into an e...

2024-05-30 21:15 3261

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, pres...

2024-05-30 18:10 5730

Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata

* Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p<0.0096) * Multiple secondary endpoints met with significant total hair re...

2024-05-30 07:05 5860

Veritas Genetics at the forefront of genomic screening with new studies presented at the European Society of Human Genetics Conference - ESHG 2024

* Veritas will present two pioneering studies at the European Society of Human Genetics Conference, inBerlin from June 1 to June 4. With a focus on elective genomic screening and newborn genomic screening, Veritas aims to set new standards in preventive medicine. * The Conference, now in its...

2024-05-29 17:55 3734

Onconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024

SEOUL, South Korea and WASHINGTON, May 29, 2024 /PRNewswire/ -- Onconic Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for oncology and gastrointestinal disorders, announced today the results of its Phase 3 ZERO-1 study of JAQBO (zastaprazan...

2024-05-29 17:35 4042

Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics

SHANGHAI, May 29, 2024 /PRNewswire/ -- Recently, Frost & Sullivan released the report "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics". I. CDMOs are advancing the biopharmaceutical industry with superior biomanufacturing capabilities...

2024-05-29 14:08 2910

Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

* Synergistic collaboration to revolutionize age-related therapies worldwide * Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an e...

2024-05-28 19:00 2585

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2024-05-28 08:00 4698

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment for Dyspepsia as Modern Antacids

Chula Medicine in collaboration with the Department of Thai Traditional and Alternative Medicine and Gastroenterologists from local medical schools proves thatThai curcumin can help treat dyspepsia as effectively as ant...

2024-05-27 11:00 4892

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine

YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-05-24 19:30 3351

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidn...

2024-05-24 19:00 4529

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...

2024-05-24 17:36 5875

CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...

2024-05-24 13:00 4462